These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 9888839

  • 1. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
    De Lucca GV, Liang J, De Lucca I.
    J Med Chem; 1999 Jan 14; 42(1):135-52. PubMed ID: 9888839
    [Abstract] [Full Text] [Related]

  • 2. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA, Jacobs K, Cornelius L, Chang CH, Jadhav PK, Holler ER, Klabe RM, Bacheler LT, Cordova B, Garber S, Reid C, Logue KA, Gorey-Feret LJ, Lam GN, Erickson-Viitanen S, Seitz SP.
    J Med Chem; 1997 May 09; 40(10):1465-74. PubMed ID: 9154969
    [Abstract] [Full Text] [Related]

  • 3. Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure-activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues.
    De Lucca GV, Kim UT, Liang J, Cordova B, Klabe RM, Garber S, Bacheler LT, Lam GN, Wright MR, Logue KA, Erickson-Viitanen S, Ko SS, Trainor GL.
    J Med Chem; 1998 Jun 18; 41(13):2411-23. PubMed ID: 9632373
    [Abstract] [Full Text] [Related]

  • 4. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
    Mimoto T, Kato R, Takaku H, Nojima S, Terashima K, Misawa S, Fukazawa T, Ueno T, Sato H, Shintani M, Kiso Y, Hayashi H.
    J Med Chem; 1999 May 20; 42(10):1789-802. PubMed ID: 10346931
    [Abstract] [Full Text] [Related]

  • 5. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q, Chang CH, Li R, Ru Y, Jadhav PK, Lam PY.
    J Med Chem; 1998 Jun 04; 41(12):2019-28. PubMed ID: 9622543
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors.
    De Lucca GV, Liang J, Aldrich PE, Calabrese J, Cordova B, Klabe RM, Rayner MM, Chang CH.
    J Med Chem; 1997 May 23; 40(11):1707-9. PubMed ID: 9171880
    [Abstract] [Full Text] [Related]

  • 7. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.
    Ax A, Schaal W, Vrang L, Samuelsson B, Hallberg A, Karlén A.
    Bioorg Med Chem; 2005 Feb 01; 13(3):755-64. PubMed ID: 15653343
    [Abstract] [Full Text] [Related]

  • 8. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM, Furfine E, Gray-Nunez Y, Spaltenstein A, Wright L.
    Bioorg Med Chem Lett; 2004 Nov 15; 14(22):5685-7. PubMed ID: 15482948
    [Abstract] [Full Text] [Related]

  • 9. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
    Sham HL, Zhao C, Stewart KD, Betebenner DA, Lin S, Park CH, Kong XP, Rosenbrook W, Herrin T, Madigan D, Vasavanonda S, Lyons N, Molla A, Saldivar A, Marsh KC, McDonald E, Wideburg NE, Denissen JF, Robins T, Kempf DJ, Plattner JJ, Norbeck DW.
    J Med Chem; 1996 Jan 19; 39(2):392-7. PubMed ID: 8558507
    [Abstract] [Full Text] [Related]

  • 10. Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.
    Melnick M, Reich SH, Lewis KK, Mitchell LJ, Nguyen D, Trippe AJ, Dawson H, Davies JF, Appelt K, Wu BW, Musick L, Gehlhaar DK, Webber S, Shetty B, Kosa M, Kahil D, Andrada D.
    J Med Chem; 1996 Jul 05; 39(14):2795-811. PubMed ID: 8709110
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.
    Lam PY, Ru Y, Jadhav PK, Aldrich PE, DeLucca GV, Eyermann CJ, Chang CH, Emmett G, Holler ER, Daneker WF, Li L, Confalone PN, McHugh RJ, Han Q, Li R, Markwalder JA, Seitz SP, Sharpe TR, Bacheler LT, Rayner MM, Klabe RM, Shum L, Winslow DL, Kornhauser DM, Hodge CN.
    J Med Chem; 1996 Aug 30; 39(18):3514-25. PubMed ID: 8784449
    [Abstract] [Full Text] [Related]

  • 13. Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.
    Kazmierski WM, Andrews W, Furfine E, Spaltenstein A, Wright L.
    Bioorg Med Chem Lett; 2004 Nov 15; 14(22):5689-92. PubMed ID: 15482949
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
    Huang PP, Randolph JT, Klein LL, Vasavanonda S, Dekhtyar T, Stoll VS, Kempf DJ.
    Bioorg Med Chem Lett; 2004 Aug 02; 14(15):4075-8. PubMed ID: 15225729
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.
    Smith AB, Cantin LD, Pasternak A, Guise-Zawacki L, Yao W, Charnley AK, Barbosa J, Sprengeler PA, Hirschmann R, Munshi S, Olsen DB, Schleif WA, Kuo LC.
    J Med Chem; 2003 May 08; 46(10):1831-44. PubMed ID: 12723947
    [Abstract] [Full Text] [Related]

  • 16. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK, Swanson LM, Cho H, Leshchenko S, Hussain KA, Kay S, Walters DE, Koh Y, Mitsuya H.
    J Med Chem; 2005 May 19; 48(10):3576-85. PubMed ID: 15887965
    [Abstract] [Full Text] [Related]

  • 17. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
    Fässler A, Bold G, Capraro HG, Cozens R, Mestan J, Poncioni B, Rösel J, Tintelnot-Blomley M, Lang M.
    J Med Chem; 1996 Aug 02; 39(16):3203-16. PubMed ID: 8759643
    [Abstract] [Full Text] [Related]

  • 18. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development.
    Bold G, Fässler A, Capraro HG, Cozens R, Klimkait T, Lazdins J, Mestan J, Poncioni B, Rösel J, Stover D, Tintelnot-Blomley M, Acemoglu F, Beck W, Boss E, Eschbach M, Hürlimann T, Masso E, Roussel S, Ucci-Stoll K, Wyss D, Lang M.
    J Med Chem; 1998 Aug 27; 41(18):3387-401. PubMed ID: 9719591
    [Abstract] [Full Text] [Related]

  • 19. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
    Garg R, Bhhatarai B.
    Bioorg Med Chem; 2004 Nov 15; 12(22):5819-31. PubMed ID: 15498658
    [Abstract] [Full Text] [Related]

  • 20. Nonpeptidic potent HIV-1 protease inhibitors.
    Prasad JV, Lunney EA, Para KS, Tummino PJ, Ferguson D, Hupe D, Domagala JM, Erickson JW.
    Drug Des Discov; 1996 Apr 15; 13(3-4):15-28. PubMed ID: 8874041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.